Received: 17 March 2022
Accepted: 27 June 2022
First Online: 8 July 2022
: This study was approved by the Ethics Evaluation Committee of Biomedical Research Project (Comité d’Evaluation de l’Ethique des projets de Recherche Biomédicale (CEERB)) Paris Nord (institutional review board—IRB 00006477 of HUPNVS, Université Paris Cité, APHP) with the following reference CER-2021-102 and registered at Clinicaltrials (NCT05124197).
: Not applicable.
: Jean-Damien Ricard: Fisher&Paykel covered travel expenses and provide high flow devices to a multicenter randomized control trial which JD Ricard is conducting on the use of nasal high flow in patients with acute hypercapnic respiratory failure. All remaining authors declare that they have no competing interests.